[Oncolytic viruses for genetic therapy of gastrointestinal tumors].
Gastroenterological oncology requires new strategies with new mechanisms of action and without cross-resistance to currently available treatment regimes. Virotherapy which is based on the employment of replication-competent viral vectors exhibiting strong oncolytic properties is such an approach currently under preclinical/clinical investigation. Techniques of molecular virology are required for further improvement of current vectors, particularly with respect to oncolytic activity, tumour selectivity, tumour spread capacity, and safety.
Bitzer
M
M
Abteilung Innere Medizin I, Medizinische Universitätsklinik, Tübingen.
Lauer
U M
UM
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D017321:Clinical Trials, Phase I as Topic; D005770:Gastrointestinal Neoplasms / Q000628:therapy*; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D008459:Measles virus / Q000235:genetics; D051379:Mice; D009154:Mutation; D009522:Newcastle disease virus / Q000235:genetics; D012087:Reoviridae / Q000235:genetics; D018139:Simplexvirus / Q000235:genetics; D014407:Tumor Cells, Cultured; D014616:Vaccinia virus / Q000235:genetics; D014721:Vesicular stomatitis Indiana virus / Q000235:genetics; D014779:Virus Replication; D014780:Viruses / Q000235:genetics*